Beckman
Coulter expands product portfolio
Since its inception,
Beckman Coulter India’s growth in India has moved ahead to
make its life sciences business triple this year.
![](/IMG/425/45425/15rank.gif)
Beckman Coulter India is a
wholly-owned direct subsidiary of Beckman Coulter, USA. Beckman Coulter
is a leading manufacturer of biomedical testing instrument systems,
tests and supplies that simplify and automate laboratory processes.
Spanning the biomedical testing continuum¯from pioneering medical
research and clinical trials to laboratory diagnostics and
point-of-care testing¯Beckman Coulter’s 200,000 installed
systems provide essential biomedical information to enhance health care
around the world. Globally, the parent company is a consequence of a
merger between Beckman Instruments and Coulter Corporation in
1998. Prior to establishing a direct subsidiary in India, for
16 years, the company was represented in India through a reputed
distribution channel.
In India, in the past fiscal, the company garnered a total turnover of
Rs 48 crore as against Rs 24 crore in fiscal 2007-08. Commenting on its
growth, Dr Chandrasekhar, managing director, Beckman Coulter India,
said, “Last year in particular was a landmark year
for our life sciences business. We tripled our business here and
overall our business is two-and-a-half times from what we were in the
first year. We did have some major breakthroughs in
centrifugation. The year 2009-10 will be the year of flow cytometery.
We launched some exciting products some of which are pretty unique be
it in the field of centrifugation and some cancer markers some of the
most advanced flow cytometery analytical systems and the most advanced
cell sorting systems.”
For Beckman Coulter India, the diagnostic and life science research
portfolios have been major growth contributors in this
subsidiary’s total sales revenue. In life sciences, the
company has a product portfolio ranging from centrifugation, research
flow cytometry, automation, proteomics, genomics and analytical
instruments. The company mainly caters to the Indian diagnostic
industry (hematology, immunochemistry and biochemistry),
biopharmaceuticals (R&D/quality control), discovery research
and government funded research institutes, pharmaceuticals and allied
industries. Amongst its portfolio of products this year,
Gallios analyzer , a new flow cytometry has been added to its kitty of
products. It is the first in a series of key flow cytometry instruments
and software reagents to be announced throughout the year.
“Overall all our businesses within the life sciences space
have done well. Centrifugation has been doing well and around 80
percent of our business comes from this portion and it has had a modest
growth of over 24 percent compared to other businesses,” said
Dr Chandrasekhar.